MedTrace Logo

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

NCT05225077 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2022-02-04

No results posted yet for this study

Summary

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Conditions

  • Renal Insufficiency, Chronic
  • Cardiac Catheterization
  • Percutaneous Coronary Intervention

Interventions

DRUG

Dapagliflozin 10 MG [Farxiga]

Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225077 on ClinicalTrials.gov